Accelerate
Human
Discovery ™
We created Sapient to drive a fundamental shift in today’s costly, slow moving, inefficient drug development process. As a discovery metabolomics lab, we help sponsors and researchers gain a deeper understanding of human biology and use biomarker-guided drug development to effectively align patients, disease, and specific therapies.
Our Platform
Integrated Biomarker Discovery Pipeline
Sapient’s integrated discovery platform leverages next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases to enable rapid discovery, population-level validation, and robust translation of small molecule biomarkers.
Accelerated
Drug Creation
Analytical Technologies
Computational Analysis
Human Biology Database
Together these technologies drive significant speed and scale advantages.
Ability to assay
>15,000
small molecule biomarkers per biosample
Capacity to analyze
>5,000
biosamples per day
Pipeline to Translation
End-to-end support from discovery to clinical implementation.
Sapient is a high complexity CLIA-certified, CAP-accredited laboratory, which means we can support rapid translation of the biomarker discoveries we make to regulated clinical applications.
After we identify biomarkers of interest through initial rLC-MS discovery screening, we can use more traditional targeted methods to develop specific metabolites into clinical assays for use in CLIA settings, and can perform and deliver the test results under CLIA.
